Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
Article in Journal of Medicinal Chemistry (March 2024)
The most recent citing publications are shown below. View all 62 publications that cite this research output on Dimensions.
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
Article in npj Precision Oncology (March 2024)
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Article in Nature Cancer (September 2023)